AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01658748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS
Description: Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
Study NCT01658748 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS
Description: Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
Study NCT02579460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of Acid Suppressing Medications
Description: Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
Study NCT03304561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation
Description: traditional ACL rehabilitation program
Study NCT03304561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-over training
Description: Cross-over training addition to the traditional rehabilidation
Study NCT03741465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The SFP technique
Description: The USG, and the 5-point NRS evaluation in the SFP
Study NCT03741465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The ASP technique
Description: The USG, and the 5-point NRS evaluation in the ASP
Study NCT00120016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary counseling
Description: telephone counseling
Study NCT01813396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint mobilization plus massage
Study NCT01813396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint mobilization/shoulder physical activity guide
Study NCT05212558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo respiratory muscle training
Description: Unloaded respiratory muscle training plus conventional respiratory exercises
Study NCT05212558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training plus conventional respiratory exercises
Study NCT05212558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training
Description: Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.
Study NCT04954508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The hug-up test
Description: It is a new physical test used to detect supraspinatus tear
Study NCT04954508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EC test
Description: It is a traditional physical test used to detect supraspinatus tear
Study NCT04954508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FC test
Description: It is a traditional physical test used to detect supraspinatus tear
Study NCT04954508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neer impingement sign
Description: It is a traditional physical test used to detect supraspinatus tear
Study NCT04954508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hawkins-Kennedy impingement sign
Description: It is a traditional physical test used to detect supraspinatus tear
Study NCT04954508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic arthroscopy
Description: The arthroscopic operation involved complete inspection of the supraspinatus. Supraspinatus tears were categorized as fullthickness tears (FTTs), which were classified as small (≤1 cm), moderate (≤3 cm), large (≤5 cm), and massive (>5 cm), on the basis of the largest dimension, and partial-thickness tears (PTTs), which were classified as bursal-sided, articular-sided,and intra-tendinous. Other combined diseases including acromioclavicular joint derangement, infraspinatus lesions, subscapularis lesions, superior labrum anterior and posterior (SLAP) lesions, biceps disorders, and Bankart lesions were recorded as well to assess the specificity of the tests.
Study NCT01067677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaclopramide
Description: 0.5 mg/kg for rescue after PONV
Study NCT01067677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 0.1 mg/kg (max 4 mg0
Study NCT01067677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: 0.25 mg/kg (max 25 mg)
Study NCT01067677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: equal volume (5 ml)as experimental rescue medications
Study NCT03761927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR enabled
Description: Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
Study NCT03761927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(1)
Description: Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
Study NCT03761927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(2)
Description: Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
Study NCT01091675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
Study NCT02721875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Study NCT02721875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT02337868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-001
Description: HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
Study NCT00729872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG011
Description: Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
Study NCT02337868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
Study NCT00348712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, 4 mg once or twice daily.
Study NCT00348712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.
Study NCT00348712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.
Study NCT02840708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Study NCT03483896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daylight Intervention
Description: Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
Study NCT00430716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral, 20 mg, tid
Study NCT00430716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral 1 mg, tid
Study NCT00430716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral 5 mg, tid
Study NCT00430716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral 20 mg, tid
Study NCT02263469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study NCT00729872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
Study NCT02794753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Study NCT02794753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Game
Study NCT03589508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person sessions: ABCP_P
Description: 6 weekly sessions of alcohol prevention conducted in person.
Study NCT03589508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video conference sessions: ABCP_T
Description: 6 weekly sessions of alcohol prevention conducted by video conference.
Study NCT02978573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartiva
Description: Cartiva Synthetic Cartilage Implant
Study NCT03699826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS for tinnitus
Description: Targeted stimulation to decrease tinnitus symptom severity.
Study NCT03056989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: Inhalation solution twice daily for 7 days.
Study NCT03324776 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afrezza Inhalant Product
Description: Mealtime Ultra-Rapid Acting Insulin
Study NCT00651924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR-based Cognitive-behavior therapy
Description: Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
Study NCT00790946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80 to 160 mg
Study NCT02552368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IpsiHand Device
Description: Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
Study NCT02908919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: The quality of bowel preparation, which is checked during colonoscopy
Study NCT01356160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, 30 mg QD
Study NCT01356160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-5885
Description: tablet, 30 mg QD
Study NCT01312636 — intervention group
Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Data will be collected at the baseline visit and approximately once a year until end of study.
Study NCT02673515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate day fasting
Description: Subjects are requested to fast every other day. Calorie free fluids are allowed.
Study NCT03616977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014 U-200
Description: Administered SC
Study NCT01356160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: tablet, 200 mg QD
Study NCT03616977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014 U-100
Description: Administered SC
Study NCT02733055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: posturographic evaluation
Description: subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
Study NCT00982995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
Study NCT03580668 — intervention group
Intervention type: DRUG
Intervention: B/F/TAF
Description: B/F/TAF administered in accordance with the approved product monograph
Study NCT03580005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate HCl ERCT
Description: methylphenidate HCl ERCT
Study NCT03580005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Match Quillichew ERCT
Study NCT02882529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
Study NCT01356160 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a
Description: (solution for injection) 180 µg/week
Study NCT01356160 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a
Description: (solution for injection) 180 µg/week
Study NCT01356160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study NCT01356160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study NCT02769403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMath EmWAVE Pro
Description: The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate
Study NCT02769403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMath EmWAVE Pro
Description: The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure and Heart Rate
Description: All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Heart Rate
Description: All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sick Days
Description: Sick days during the 12 week study period will be collected
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sick Days
Description: Sick days during the 12 week study period will be collected
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Satisfaction
Description: This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.
Study NCT02769403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction
Description: This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.
Study NCT04355247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MethylPREDNISolone 80 Mg/mL Injectable Suspension
Description: * Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital.
Study NCT04330352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based STOP touching your face practice
Description: 1. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
Study NCT01356160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9451 Placebo
Description: Placebo to match GS-9451 QD
Study NCT01269866 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cymbalta
Description: Cymbalta 60 to 120 mg PO QD
Study NCT01261637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 20ml saline
Study NCT01261637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: 0.25% ropivicaine (maximum 1.5mg/kg)
Study NCT05249023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium butyrate bolus
Description: On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
Study NCT00960063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide